Wednesday 20 September 2017

Angiotensin Converting Enzyme (ACE) Inhibitors Market 2017 to 2025 - Growth, Trends and Forecast by Acute Market Reports

Angiotensin Converting Enzyme (ACE) Inhibitors Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025, the angiotensin converting enzyme (ACE) inhibitors market was valued at USD 11,591.8 Mn in 2017, and is expected to reach USD 11,649.3 Mn by 2025, expanding at a CAGR of (0.5%) from 2017 to 2025.


Market Insights
ACE inhibitors are class of drugs (angiotensin-converting enzyme inhibitors) that block the conversion of angiotensin I to angiotensin II, used in the treatment of hypertension and congestive heart failure and in the prevention of microvascular complications of diabetes mellitus. According to World Health Organization (WHO), globally cardiovascular disease accounts for approximately 17 million deaths a year, nearly one third of the total. Of these, complications of hypertension account for 9.4 million deaths worldwide every year ACE inhibitors market is segmented on the basis of application and type of drug.
The type of drug segment comprises of benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril,perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. All ACE inhibitors bind to tissue and plasma protein. Whereas free drug is eliminated relatively rapidly by the kidney predominantly by glomerular filtration, binding to tissue sites means that the plasma concentration-time profile shows a long lasting terminal elimination phase.
The prototype ACE inhibitor, captopril, is absorbed and eliminated rapidly. Enalapril, like most of the later ACE inhibitors, is an inactive pro-drug that requires hydrolysis during or after absorption to generate the active acid form, enalaprilat. Lisinopril is an analogue of enalapril and is itself active.


Geography segmentation of ACE inhibitors comprised regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. North America was observed as the largest regional market for ACE inhibitors market. North America constitutes regional markets of U.S. and Canada, the rising prevalence of cardiovascular and kidney diseases, mounting obesity in the population and supportive reimbursement policies are the key drivers for periodical growth of ACE inhibitors market in this region. The developed healthcare infrastructure, and high public awareness related to diagnosis, treatment and management of lifestyle diseases are the key factors assisting the growth of North America ACE inhibitors market.
Market Competition Assessment:
The ACE inhibitors market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.
Key Market Movements:
• Lisinopril and ramipril are most popular than comparable drugs due to dosage convenience, good insurance coverage, and higher efficiency along with low side-effects
• The rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market
• Chronic kidney disorders application segment was observed as the fastest moving segment in overall ACE inhibitors market throughout the forecast period"


Table of Content :
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2015 - 2025 (Value %)
2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Application Type, 2015 (USD Mn)
2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2015 (Value %)
Chapter 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
3.1 Overview
3.2 Market Drivers
3.3 Market Restraints
3.4 Market Opportunities
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Angiotensin Converting Enzyme (ACE) Inhibitors, by Key Players
Chapter 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Drug Type
4.1 Overview
4.2 Benazepril
4.3 Captopril
4.4 Enalapril
4.5 Fosinopril
4.6 Lisinopril
4.7 Moexipril
4.8 Perindopril
4.9 Quinapril
4.10 Ramipril
4.11 Trandolapril
4.12 Combination ACE Inhibitors
Chapter 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Applications
5.1 Overview
5.2 Hypertension
5.3 Coronary Artery Diseases
5.4 Heart Failure
5.5 Myocardial Infarction
5.6 Diabetes
5.7 Chronic Kidney Disorders
5.8 Others (Scleroderma, Migraine and others)

Latest Reports:

About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.

Contact Us:
Name : Chris Paul
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)